These differences may be explained by the fact that EMAYIC included a large, representative cohort of real-world patients with “true” HF, subgrouped according to current guidelines and stringent inclusion criteria to minimize false positives and enhance specificity in HF diagnosis (i.e., NT-proBNP ≥ 600 pg/mL). The gene discussed is NPPB; the disease is hydrops fetalis.